Drug Development Pipeline
VX-659 + tezacaftor + ivacaftor
Restore CFTR Function
This program tested VX-659 in combination with tezacaftor and ivacaftor. VX-659 and tezacaftor (VX-661) are CFTR correctors. Correctors are drugs designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, ivacaftor helps facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell.
A phase 2 study of VX-659 in adults with CF showed that VX-659 was associated with improvements in lung function, sweat chloride and quality of life.
Two phase 3 studies to test the safety and effectiveness of VX-659 in people with CF age 12 years or older have been completed. No further development in CF is planned.
This program is sponsored by Vertex Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. This program was conducted within the Therapeutics Development Network (TDN).
Recent VX-659 + tezacaftor + ivacaftor Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More